InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 03/21/2019 12:30:39 PM

Thursday, March 21, 2019 12:30:39 PM

Post# of 15799
News: $OPK OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

MIAMI, March 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and obesity.  OPK88003 is a once-weekly injectable oxyntomodulin compound with glucagon-li...

Find out more https://marketwirenews.com/news-releases/opko-announces-positive-topline-results-in-phase-2-diabetes-and-obesity-trial-7860918.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News